{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"76.500","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,227,863,545","primaryexch":"香港交易所","ric":"2268.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.8925,"inline_upper_strike_price":"","sedol":"BQHNQ38","am":"259.87","iv":"","ew_strike":"","as":"74.550","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"74.500","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"18.520","shares_issued_date":"2025年9月10日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"陳智勝","underlying_ric":"2268.HK","hi52":"78.550","issuer_name":"藥明合聯生物技術有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"73.000","mkt_cap":"91.47","f_aum_hkd":null,"ew_sub_per_to":"","ls":"74.500","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-2.250","aum":"","issued_shares_class_B":null,"vo":"3.47","secondary_listing_flag":false,"listing_date":"2023年11月17日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"藥明合聯生物技術有限公司","nm_s":"藥明合聯","sym":"2268","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"藥明合聯生物技術有限公司是一家主要從事提供提供抗体偶联药物（ADC）及其他生物偶聯藥物的全面合同研究、開發及製造組織（CRDMO）服務的投資控股公司。該公司的服務包括生物偶聯藥物、單克隆抗體中間體及生物偶聯藥物相關連接子及有效載荷的發現、工藝開發及優良生產質量管理規範（GMP）生產。該公司透過按有償服務（FFS）基準的合約和按全時當量（FTE）基準的合約向客戶提供CRDMO服務。該公司主要在國內市場、北美、歐洲和世界其他地區市場開展業務。","op":"74.950","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>勿地臣街1號<br/>時代廣場<br/>二座31樓","pc":"-2.93","days_to_expiry":null,"underlying_code":null,"pe":"78.78","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"76.750","isin":"KYG9808A1058","moneyness":""}},"qid":"1759074067479"}
